CRSwNP review highlights endotype-driven therapy relevance to AERD
Key Questions
What is the overlap between AERD, CRSwNP, and asthma?
AERD (Aspirin-Exacerbated Respiratory Disease) overlaps with CRSwNP (Chronic Rhinosinusitis with Nasal Polyps) and asthma, particularly in the Type 2 endotype. Biomarkers such as eosinophils, FeNO, IgE, and periostin guide biologics therapy in these conditions.
What biomarkers indicate Type 2 endotype in CRSwNP?
Type 2 endotype biomarkers include eosinophils, FeNO (fractional exhaled nitric oxide), IgE, and periostin. These markers help personalize diagnosis and treatment, aligning with GINA 2025/2026 guidelines for AERD patients.
How does dupilumab fit into CRSwNP treatment?
Dupilumab is reinforced by post-FESS (Functional Endoscopic Sinus Surgery) data for managing recurrent nasal polyps after steroids. It targets Type 2 inflammation in CRSwNP, especially in AERD overlap cases.
What is Samter's triad or NERD?
Samter's triad, also known as NERD (NSAID-Exacerbated Respiratory Disease), involves asthma, nasal polyps, and NSAID sensitivity. Related articles overview its pathogenesis, diagnosis, and links to aspirin-induced asthma.
What resources are available from the AAFA PEACE-NP launch?
The AAFA PEACE-NP launch provides videos and a checklist for nasal polyposis management. It supports FeNO testing for personalized diagnosis and pre-desensitization, alongside a nasal polyposis PDF with pathogenesis and over 250 treatment algorithms.
AERD overlaps CRSwNP/asthma with Type 2 endotype biomarkers (eosinophils/FeNO/IgE/periostin) guiding biologics. Nasal polyposis PDF adds pathogenesis/250+ algorithms for medical/surgical treatments, reinforcing dupilumab post-FESS data, recurrent polyps post-steroids, Samter's triad/NERD overview, AAFA PEACE-NP launch (videos/checklist), GINA 2025/2026 biomarkers; FeNO testing aligns for personalized dx/pre-desensitization.